Dr. Younes Discusses the Future of Treating Lymphoid Malignancies

Anas Younes, MD
Published Online: Tuesday, May 6, 2014
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of treating lymphoid malignancies.

In a session at the 18th Annual International Congress on Hematologic Malignancies®, oncologists discussed how to select patients with lymphoid malignancies for therapy in this era of molecularly-defined subsets of disease. Though tools exist to define mutations in certain diseases, they are not yet guiding therapy in lymphoid malignancies. Younes says he believes this is the future.

There remains a need to learn more about disease subsets and place patients in clinical trials to personalize treatments. This movement from treating all patients with R-CHOP to dissecting disease and offering treatments accordingly will represent a culture change.

Online CME Activities
Free CME from PER
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
Community Practice Connections: 15th Annual International Lung Cancer Congress®
Community Practice Connections: 13th Annual International Congress on the Future of Breast Cancer®
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
More Reading
$auto_registration$